BCLI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BCLI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Brainstorm Cell Therapeutics's YoY EPS Growth for the quarter that ended in Sep. 2024 was -13.33%.
Brainstorm Cell Therapeutics's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.51.
The historical data trend for Brainstorm Cell Therapeutics's YoY EPS Growth can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brainstorm Cell Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
YoY EPS Growth | Get a 7-Day Free Trial | -51.43 | -0.94 | 36.45 | 2.94 | 39.39 |
Brainstorm Cell Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
YoY EPS Growth | Get a 7-Day Free Trial | 84.21 | 15.38 | 64.29 | 69.23 | -13.33 |
YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.
Brainstorm Cell Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:
YoY EPS Growth (A: Dec. 2023 ) | |||||
= | (Earnings per Share (Diluted) (A: Dec. 2023 ) | - | Earnings per Share (Diluted) (A: Dec. 2022 )) | / | | Earnings per Share (Diluted) (A: Dec. 2022 ) | |
= | (-6 | - | -9.9) | / | | -9.9 | |
= | 39.39 % |
Brainstorm Cell Therapeutics's YoY EPS Growth for the quarter that ended in Sep. 2024 is calculated as:
YoY EPS Growth (Q: Sep. 2024 ) | |||||
= | (Earnings per Share (Diluted) (Q: Sep. 2024 ) | - | Earnings per Share (Diluted) (Q: Sep. 2023 )) | / | | Earnings per Share (Diluted) (Q: Sep. 2023 )) | |
= | (-0.51 | - | -0.45) | / | | -0.45 | |
= | -13.33 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.
Chaim Lebovits | officer: Chief Executive Officer | 110 EAST 59TH STREET, NEW YORK NY 10019 |
Stacy Lindborg | officer: EVP, Head Global Clin Research | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019 |
Nir Naor | director | BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019 |
Kirk Taylor | officer: Chief Medical Officer | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019 |
Menghisteab Bairu | director | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019 |
Alla Patlis | officer: See Remarks | C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601 |
Anthony Waclawski | officer: See Remarks | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019 |
David Setboun | officer: EVP and COO | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019 |
Acc International Holdings Ltd. | other: Member of 10% owner group | MORGAN & MORGAN BUILDING, PASEA ESTATE, ROAD TOWN, TORTOLA D8 VG 1110 |
Sankesh Abbhi | director | 3119 PONCE DE LEON, UNIT C, CORAL GABLES FL 33134 |
Jacob A Frenkel | director | 188 E. 70TH ST., #29A, NEW YORK NY 10021 |
Arturo Araya | officer: Chief Commercial Officer | C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601 |
Preetam Shah | officer: EVP, CFO and Treasurer | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019 |
Ralph Dr. Kern | officer: COO and Chief Medical Officer | C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601 |
Irit Arbel | director | 6 HADISHON STREEET, JERUSALEM, ISRAEL 96596 L3 00000 |
From GuruFocus
By PRNewswire • 02-13-2024
By PRNewswire • 04-09-2024
By PRNewswire • 06-20-2024
By PRNewswire • 07-24-2024
By PRNewswire • 08-07-2024
By PRNewswire • 04-01-2024
By GuruFocus Research • 08-17-2024
By PRNewswire • 11-14-2024
By PRNewswire • 05-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.